Literature DB >> 17339337

The MDM2 ubiquitination signal in the DNA-binding domain of p53 forms a docking site for calcium calmodulin kinase superfamily members.

Ashley L Craig1, Jennifer A Chrystal, Jennifer A Fraser, Nathalie Sphyris, Yao Lin, Ben J Harrison, Mary T Scott, Irena Dornreiter, Ted R Hupp.   

Abstract

Genetic and biochemical studies have shown that Ser(20) phosphorylation in the transactivation domain of p53 mediates p300-catalyzed DNA-dependent p53 acetylation and B-cell tumor suppression. However, the protein kinases that mediate this modification are not well defined. A cell-free Ser(20) phosphorylation site assay was used to identify a broad range of calcium calmodulin kinase superfamily members, including CHK2, CHK1, DAPK-1, DAPK-3, DRAK-1, and AMPK, as Ser(20) kinases. Phosphorylation of a p53 transactivation domain fragment at Ser(20) by these enzymes in vitro can be mediated in trans by a docking site peptide derived from the BOX-V domain of p53, which also harbors the ubiquitin signal for MDM2. Evaluation of these calcium calmodulin kinase superfamily members as candidate Ser(20) kinases in vivo has shown that only CHK1 or DAPK-1 can stimulate p53 transactivation and induce Ser(20) phosphorylation of p53. Using CHK1 as a prototypical in vivo Ser(20) kinase, we demonstrate that (i) CHK1 protein depletion using small interfering RNA can attenuate p53 phosphorylation at Ser(20), (ii) an enhanced green fluorescent protein (EGFP)-BOX-V fusion peptide can attenuate Ser(20) phosphorylation of p53 in vivo, (iii) the EGFP-BOX-V fusion peptide can selectively bind to CHK1 in vivo, and (iv) the Deltap53 spliced variant lacking the BOX-V motif is refractory to Ser(20) phosphorylation by CHK1. These data indicate that the BOX-V motif of p53 has evolved the capacity to bind to enzymes that mediate either p53 phosphorylation or ubiquitination, thus controlling the specific activity of p53 as a transcription factor.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17339337      PMCID: PMC1899961          DOI: 10.1128/MCB.01595-06

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  56 in total

1.  Signaling to p53: the use of phospho-specific antibodies to probe for in vivo kinase activation.

Authors:  Ashley L Craig; Susan E Bray; Lee E Finlan; Neil M Kernohan; Ted R Hupp
Journal:  Methods Mol Biol       Date:  2003

2.  DNA-dependent acetylation of p53 by the transcription coactivator p300.

Authors:  David Dornan; Harumi Shimizu; Neil D Perkins; Ted R Hupp
Journal:  J Biol Chem       Date:  2002-12-23       Impact factor: 5.157

3.  The proline repeat domain of p53 binds directly to the transcriptional coactivator p300 and allosterically controls DNA-dependent acetylation of p53.

Authors:  David Dornan; Harumi Shimizu; Lindsay Burch; Amanda J Smith; Ted R Hupp
Journal:  Mol Cell Biol       Date:  2003-12       Impact factor: 4.272

Review 4.  Drug discovery and p53.

Authors:  David P Lane; Ted R Hupp
Journal:  Drug Discov Today       Date:  2003-04-15       Impact factor: 7.851

Review 5.  Signalling specificity of Ser/Thr protein kinases through docking-site-mediated interactions.

Authors:  Ricardo M Biondi; Angel R Nebreda
Journal:  Biochem J       Date:  2003-05-15       Impact factor: 3.857

6.  The development of a CDK2-docking site peptide that inhibits p53 and sensitizes cells to death.

Authors:  Michelle Ferguson; M Gloria Luciani; Lee Finlan; Elaine M Rankin; Sally Ibbotson; Alan Fersht; Tedd R Hupp
Journal:  Cell Cycle       Date:  2004-01       Impact factor: 4.534

7.  Phage-peptide display identifies the interferon-responsive, death-activated protein kinase family as a novel modifier of MDM2 and p21WAF1.

Authors:  Lindsay R Burch; Mary Scott; Elizabeth Pohler; David Meek; Ted Hupp
Journal:  J Mol Biol       Date:  2004-03-12       Impact factor: 5.469

8.  Allosteric effects mediate CHK2 phosphorylation of the p53 transactivation domain.

Authors:  Ashley Craig; Mary Scott; Lindsay Burch; Graeme Smith; Kathryn Ball; Ted Hupp
Journal:  EMBO Rep       Date:  2003-08       Impact factor: 8.807

9.  The Chk2 tumor suppressor is not required for p53 responses in human cancer cells.

Authors:  Prasad V Jallepalli; Christoph Lengauer; Bert Vogelstein; Fred Bunz
Journal:  J Biol Chem       Date:  2003-03-24       Impact factor: 5.157

10.  Questioning the role of checkpoint kinase 2 in the p53 DNA damage response.

Authors:  Jinwoo Ahn; Marshall Urist; Carol Prives
Journal:  J Biol Chem       Date:  2003-03-24       Impact factor: 5.157

View more
  20 in total

1.  Regulation of the E3 ubiquitin ligase activity of MDM2 by an N-terminal pseudo-substrate motif.

Authors:  Erin G Worrall; Bartosz Wawrzynow; Liam Worrall; Malcolm Walkinshaw; Kathryn L Ball; Ted R Hupp
Journal:  J Chem Biol       Date:  2009-05-16

2.  Simian virus 40 activates ATR-Delta p53 signaling to override cell cycle and DNA replication control.

Authors:  Gabor Rohaly; Katharina Korf; Silke Dehde; Irena Dornreiter
Journal:  J Virol       Date:  2010-08-04       Impact factor: 5.103

3.  Death-associated protein kinase 1 promotes growth of p53-mutant cancers.

Authors:  Jing Zhao; Dekuang Zhao; Graham M Poage; Abhijit Mazumdar; Yun Zhang; Jamal L Hill; Zachary C Hartman; Michelle I Savage; Gordon B Mills; Powel H Brown
Journal:  J Clin Invest       Date:  2015-06-15       Impact factor: 14.808

4.  Cooperative functions of Chk1 and Chk2 reduce tumour susceptibility in vivo.

Authors:  Hiroyuki Niida; Kazuhiro Murata; Midori Shimada; Kumiko Ogawa; Kumiko Ohta; Kyoko Suzuki; Hidetsugu Fujigaki; Aik Kia Khaw; Birendranath Banerjee; M Prakash Hande; Tomomi Miyamoto; Ichiro Miyoshi; Tomoyuki Shirai; Noboru Motoyama; Mireille Delhase; Ettore Appella; Makoto Nakanishi
Journal:  EMBO J       Date:  2010-09-10       Impact factor: 11.598

5.  A novel p53 phosphorylation site within the MDM2 ubiquitination signal: II. a model in which phosphorylation at SER269 induces a mutant conformation to p53.

Authors:  Jennifer A Fraser; Arumugam Madhumalar; Elizabeth Blackburn; Janice Bramham; Malcolm D Walkinshaw; Chandra Verma; Ted R Hupp
Journal:  J Biol Chem       Date:  2010-09-16       Impact factor: 5.157

6.  Oncogenic miR-17/20a Forms a Positive Feed-forward Loop with the p53 Kinase DAPK3 to Promote Tumorigenesis.

Authors:  Zhiqiang Cai; Ran Cao; Kai Zhang; Yuanchao Xue; Chen Zhang; Yu Zhou; Jie Zhou; Hui Sun; Xiang-Dong Fu
Journal:  J Biol Chem       Date:  2015-06-27       Impact factor: 5.157

7.  A central role for CK1 in catalyzing phosphorylation of the p53 transactivation domain at serine 20 after HHV-6B viral infection.

Authors:  Nicola J MacLaine; Bodil Oster; Bettina Bundgaard; Jennifer A Fraser; Carolyn Buckner; Pedro A Lazo; David W Meek; Per Höllsberg; Ted R Hupp
Journal:  J Biol Chem       Date:  2008-07-31       Impact factor: 5.157

Review 8.  Roles of Chk1 in cell biology and cancer therapy.

Authors:  Youwei Zhang; Tony Hunter
Journal:  Int J Cancer       Date:  2013-05-28       Impact factor: 7.396

9.  The regulation of p53 by phosphorylation: a model for how distinct signals integrate into the p53 pathway.

Authors:  Nicola J Maclaine; Ted R Hupp
Journal:  Aging (Albany NY)       Date:  2009-05-07       Impact factor: 5.682

10.  The alternative splice variant of DAPK-1, s-DAPK-1, induces proteasome-independent DAPK-1 destabilization.

Authors:  Yao Lin; Craig Stevens; Ben Harrison; Suresh Pathuri; Eliana Amin; Ted R Hupp
Journal:  Mol Cell Biochem       Date:  2009-03-08       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.